Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 2/20 | 1.00 |
| ▸ | DPP4 | P27487 | 1/20 | 1.00 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.84 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.84 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.84 |
| ▸ | MAPT | P10636 | 3/20 | 0.82 |
| ▸ | MEN1 | O00255 | 3/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.82 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.82 |
| ▸ | LMNA | P02545 | 2/20 | 0.82 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.82 |
| ▸ | IPMK | Q8NFU5 | 2/20 | 0.82 |
| ▸ | IP6K2 | Q9UHH9 | 2/20 | 0.82 |
| ▸ | APP | P05067 | 1/20 | 0.82 |
| ▸ | THRB | P10828 | 1/20 | 0.82 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.82 |
| ▸ | RECQL | P46063 | 1/20 | 0.82 |
| ▸ | ELAVL3 | Q14576 | 1/20 | 0.82 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.82 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ombuine SCHEMBL31516400 | 1.00 | XDH (1.00) | XDHDPP4CYP1A1CYP1A2CYP1B1 | |
| Ombuine SCHEMBL29475881 | 1.00 | XDH (1.00) | XDHDPP4CYP1A1CYP1A2CYP1B1 | |
| SCHEMBL1250547 | 0.93 | XDH (0.86) | XDHDPP4CYP1A1CYP1A2CYP1B1 | |
| Tamarixetin SCHEMBL892776 | 0.91 | CYP1A2 (1.00) | XDHDPP4CYP1A1CYP1A2CYP1B1 | |
| Tamarixetin SCHEMBL29750609 | 0.91 | CYP1A2 (1.00) | XDHDPP4CYP1A1CYP1A2CYP1B1 | |
| Tamarixetin SCHEMBL30255798 | 0.91 | CYP1A2 (1.00) | XDHDPP4CYP1A1CYP1A2CYP1B1 | |
| Rhamnazin SCHEMBL39443 | 0.90 | MEN1 (0.84) | XDHDPP4CYP1A1CYP1A2CYP1B1 | |
| Rhamnazin SCHEMBL29724889 | 0.90 | MEN1 (0.84) | XDHDPP4CYP1A1CYP1A2CYP1B1 | |
| Rhamnetin SCHEMBL7164573 | 0.90 | MEN1 (1.00) | XDHDPP4CYP1A1CYP1A2CYP1B1 | |
| Rhamnetin SCHEMBL555118 | 0.90 | MEN1 (1.00) | XDHDPP4CYP1A1CYP1A2CYP1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117777079-A | Synthesis method and application of 4', 7-O-dimethyl quercetin | 常州大学 | 2024-03-29 | — | — | CN | claimed |
| US-20110034427-A1 | Anti-aging properties of quercetin, 18alpha-glycyrrhetinic acid and hederagenin and their derivatives | KORRES S.A. NATURAL PRODUCTS (GR) | 2011-02-10 | — | — | US | claimed |
| CN-114031656-B | Medicine for treating urinary system lithiasis related diseases and preparation method thereof | 张弘 | 2025-05-27 | — | — | CN | disclosed |
| US-20240115645-A1 | DRUG FOR TREATING UROLITHIASIS-RELATED DISEASE, AND PREPARATION METHOD THEREFOR | HONG ZHANG (CN) | 2024-04-11 | — | — | US | disclosed |
| CN-117777079-A | Synthesis method and application of 4', 7-O-dimethyl quercetin | 常州大学 | 2024-03-29 | — | — | CN | disclosed |
| CN-117777079-A | Synthesis method and application of 4', 7-O-dimethyl quercetin | 常州大学 | 2024-03-29 | — | — | CN | disclosed |
| CN-117777079-A | Synthesis method and application of 4', 7-O-dimethyl quercetin | 常州大学 | 2024-03-29 | — | — | CN | disclosed |
| WO-2024035859-A1 | COMBINATION THERAPIES FOR TREATING INFLAMMATION | FLAGSHIP PIONEERING INNOVATIONS VI, LLC (US) | 2024-02-15 | — | — | WO | disclosed |
| US-11839637-B2 | Neuron activator | KINJIRUSHI CO., LTD. (JP) | 2023-12-12 | — | — | US | disclosed |
| US-11839637-B2 | Neuron activator | KINJIRUSHI CO., LTD. (JP) | 2023-12-12 | — | — | US | disclosed |
| WO-2022151978-A1 | DRUG FOR TREATING UROLITHIASIS-RELATED DISEASE, AND PREPARATION METHOD THEREFOR | 张弘 | 2022-07-21 | — | — | WO | disclosed |
| US-20210299199-A1 | Neuron activator | KINJIRUSHI CO., LTD. (JP) | 2021-09-30 | — | — | US | disclosed |
| US-11065288-B2 | Neuron activator | KINJIRUSHI CO., LTD. (JP) | 2021-07-20 | — | — | US | disclosed |
| US-20190099462-A1 | Neuron activator | KINJIRUSHI CO., LTD. (JP) | 2019-04-04 | — | — | US | disclosed |
| US-8367121-B2 | Nutraceutical agent for attenuating the neurodegenerative process associated with Parkinson's disease | FLORIDA A & M UNIVERSITY (US) | 2013-02-05 | — | — | US | disclosed |
| CN-102359014-A | Natural anti-microbial fabric containing wrinkled giant hyssop extractive and preparation method thereof | WUJIANG LANRUITE TEXTILE PRODUCT CO LTD | 2012-02-22 | — | — | CN | disclosed |
| US-20110034427-A1 | Anti-aging properties of quercetin, 18alpha-glycyrrhetinic acid and hederagenin and their derivatives | KORRES S.A. NATURAL PRODUCTS (GR) | 2011-02-10 | — | — | US | disclosed |
| US-20100150895-A1 | Nutraceutical agent for attenuating the Neurodegenerative process associated with Parkinson's disease | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-06-17 | — | — | US | disclosed |
| US-20080292607-A1 | Nutraceutical agent for attenuating the neurodegenerative process associated with Parkinson's disease | MAZZIO ELIZABETH | 2008-11-27 | — | — | US | disclosed |
| US-20070116779-A1 | Comprehensive nutraceutical agent for treatment/ prevention of Parkinson's disease | MAZZIO ELIZABETH | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034427-A1 | Anti-aging properties of quercetin, 18alpha-glycyrrhetinic acid and hederagenin and their derivatives | GLA, AGER, CUTA | XDH 1360/4885DPP4 2177/4885CYP1A1 1329/4885 |
| US-20190099462-A1 | Neuron activator | BDNF, DBH, CHAT | XDH 3081/4885DPP4 796/4885CYP1A1 4486/4885 |
| US-11065288-B2 | Neuron activator | BDNF, DBH, CHAT | XDH 3081/4885DPP4 796/4885CYP1A1 4486/4885 |
| US-20240115645-A1 | DRUG FOR TREATING UROLITHIASIS-RELATED DISEASE, AND PREPARATION METHOD THEREFOR | HK1, HKDC1, HK2 | XDH 287/4885DPP4 3351/4885CYP1A1 3173/4885 |
| US-20210299199-A1 | Neuron activator | BDNF, DBH, CHAT | XDH 3081/4885DPP4 796/4885CYP1A1 4486/4885 |
| US-11839637-B2 | Neuron activator | BDNF, DBH, CHAT | XDH 3081/4885DPP4 796/4885CYP1A1 4486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.